H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics to $17 from $19 and keeps a Buy rating on the shares. The analyst says the MORPHEUS trial results set up another potential combination for inavolisib.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RLAY:
- Relay Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
- Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
- Relay Therapeutics reports Q3 EPS (54c), consensus (83c)
- Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
